Vivos Therapeutics (VVOS) Total Non-Current Liabilities (2022 - 2026)

Vivos Therapeutics (VVOS) has 4 years of Total Non-Current Liabilities data on file, last reported at $25.0 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $25.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $25.0 million (changed N/A YoY), and the FY2025 annual result was $25.4 million, changed N/A from the prior year.
• Total Non-Current Liabilities declined to $25.0 million in Q1 2026 per VVOS's latest filing, from $25.4 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $25.4 million in Q4 2025 and troughed at $8.4 million in Q1 2022.
• A 4-year average of $16.1 million and a median of $14.9 million in 2023 frame the typical range for Total Non-Current Liabilities.
• On a YoY basis, Total Non-Current Liabilities climbed as much as 4.38% in 2023 and fell as far as 4.38% in 2023.
• A 4-year view of Total Non-Current Liabilities shows it stood at $8.4 million in 2022, then gained by 15.49% to $9.7 million in 2023, then jumped by 161.88% to $25.4 million in 2025, then fell by 1.54% to $25.0 million in 2026.
• Business Quant data shows VVOS's Total Non-Current Liabilities at $25.0 million in Q1 2026, $25.4 million in Q4 2025, and $21.7 million in Q3 2025.